BioSpace News Archive

Nemysis Ltd and Bruno Farmaceutici SpA are pleased to announce they have signed a non-exclusive sales and marketing agreement for IHAT, Nemysis’ innovative oral iron supplementation product.

Kashiv Biosciences, LLC announced that ADL018, a biosimilar candidate to Xolair®, completed a successful global Phase 1 clinical study in healthy volunteers.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in a fireside chat at TD Cowen’s 2nd Annual RNA Therapeutics Summit on Monday, July 10, 2023.

Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, is pleased to announce a research and development (R&D) strategy update, aimed at expediting its clinical program of SPL028.

Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the second quarter 2023 after the close of trading on Tuesday, August 1.

TiumBio Co., Ltd. and Hansoh Pharmaceutical Group Co., Ltd. announced that the China National Medical Products Administration (NMPA) approved Hansoh’s Investigational New Drug (IND) application for clinical study of HS-10518 (also known as TU2670), the management of moderate to severe pain associated with endometriosis.

Poseida Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for P-CD19CD20-ALLO1, the Company’s first allogeneic dual CAR-T cell product candidate, which targets both CD19 and CD20 antigens for the treatment of relapsed or refractory B-cell malignancies and is being developed in partnership with Roche.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the second quarter 2023 before the market opens on Wednesday, July 26, 2023, and will hold a conference call on the same day at 8:30 a.m. EDT.

SK bioscience and the Government Pharmaceutical Organization agreed to establish a pandemic response platform, encompassing not only Thailand but extending its reach to the broader Southeast Asia region.

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2023 on Monday, July 31, after the market closes.